These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 20513503

  • 1. Editorial comment.
    Lee WR.
    Urology; 2010 Jun; 75(6):1416-7; author reply 1417. PubMed ID: 20513503
    [No Abstract] [Full Text] [Related]

  • 2. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men aged<or=55 years with favorable prostate cancer.
    Gómez-Iturriaga Piña A, Crook J, Borg J, Lockwood G, Fleshner N.
    Urology; 2010 Jun; 75(6):1412-6. PubMed ID: 20035986
    [Abstract] [Full Text] [Related]

  • 3. Clinical and physical determinants for toxicity of 125-I seed prostate brachytherapy.
    Albertsen PC.
    J Urol; 2005 Nov; 174(5):1969-70. PubMed ID: 16217368
    [No Abstract] [Full Text] [Related]

  • 4. Loose seeds versus stranded seeds in I-125 prostate brachytherapy: differences in clinical outcome.
    Hinnen KA, Moerland MA, Battermann JJ, van Roermund JG, Monninkhof EM, Jürgenliemk-Schulz IM, van Vulpen M.
    Radiother Oncol; 2010 Jul; 96(1):30-3. PubMed ID: 20215039
    [Abstract] [Full Text] [Related]

  • 5. Permanent source brachytherapy for prostate cancer. American College of Radiology. ACR Appropriateness Criteria.
    Potters L, Perez CA, Beyer DC, Blasko JC, Forman JD, Hussey DH, Lee WR, Paryani SB, Pollack A, Roach M, Scardino P, Schellhammer P, Leibel S.
    Radiology; 2000 Jun; 215 Suppl():1383-400. PubMed ID: 11037554
    [No Abstract] [Full Text] [Related]

  • 6. Re: Dosimetric consequences of increased seed strength for I-125 prostate implants. Radiother Oncol. 2003 Sep;68(3):295-7.
    Lee WR.
    Radiother Oncol; 2004 Feb; 70(2):209-10; author reply 210. PubMed ID: 15028411
    [No Abstract] [Full Text] [Related]

  • 7. [Initial experiences with iodine-121 implantation in 41 patients with prostatic carcinoma].
    Battermann JJ, Boon TA, Beijert M, de Voogt HJ.
    Ned Tijdschr Geneeskd; 1987 Sep 05; 131(36):1573-6. PubMed ID: 3670438
    [No Abstract] [Full Text] [Related]

  • 8. Prostate-specific antigen bounce after permanent iodine-125 prostate brachytherapy--an Australian analysis.
    Zwahlen DR, Smith R, Andrianopoulos N, Matheson B, Royce P, Millar JL.
    Int J Radiat Oncol Biol Phys; 2011 Jan 01; 79(1):179-87. PubMed ID: 20378267
    [Abstract] [Full Text] [Related]

  • 9. [Brachytherapy for localised prostate cancer].
    Peiffert D.
    Cancer Radiother; 2007 Nov 01; 11(6-7):373-8. PubMed ID: 17962060
    [Abstract] [Full Text] [Related]

  • 10. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
    Demanes DJ, Brandt D, Schour L, Hill DR.
    Am J Clin Oncol; 2009 Aug 01; 32(4):342-7. PubMed ID: 19398902
    [Abstract] [Full Text] [Related]

  • 11. Survival after prostate brachytherapy in patients aged 60 years and younger.
    Hinnen KA, Roeloffzen EM, Battermann JJ, Van Moorselaar RJ, van Roermund JG, van Vulpen M.
    BJU Int; 2011 Jun 01; 107(12):1906-11. PubMed ID: 21062393
    [Abstract] [Full Text] [Related]

  • 12. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.
    Dattoli M, Wallner K, True L, Cash J, Sorace R.
    Urology; 2007 Feb 01; 69(2):334-7. PubMed ID: 17320673
    [Abstract] [Full Text] [Related]

  • 13. A new model using number of needles and androgen deprivation to predict chronic urinary toxicity for high or low dose rate prostate brachytherapy.
    Vargas C, Ghilezan M, Hollander M, Gustafson G, Korman H, Gonzalez J, Martinez A.
    J Urol; 2005 Sep 01; 174(3):882-7. PubMed ID: 16093980
    [Abstract] [Full Text] [Related]

  • 14. Monotherapeutic brachytherapy for clinically organ-confined prostate cancer.
    Merrick GS, Butler WM, Wallner KE, Galbreath RW, Adamovich E.
    W V Med J; 2005 Sep 01; 101(4):168-71. PubMed ID: 16296198
    [Abstract] [Full Text] [Related]

  • 15. Impact of brachytherapy on regional, racial, marital status, and age-related patterns of definitive treatment for clinically localized prostate carcinoma.
    Copeland LA, Elshaikh MA, Jackson J, Penner LA, Underwood W.
    Cancer; 2005 Oct 01; 104(7):1372-80. PubMed ID: 16118801
    [Abstract] [Full Text] [Related]

  • 16. Treatment outcomes and quality-of-life issues for patients treated with prostate brachytherapy.
    Abel L, Dafoe-Lambie J, Butler WM, Merrick GS.
    Clin J Oncol Nurs; 2003 Oct 01; 7(1):48-54. PubMed ID: 12629934
    [Abstract] [Full Text] [Related]

  • 17. Outcomes following iodine-125 monotherapy for localized prostate cancer: the results of leeds 10-year single-center brachytherapy experience.
    Henry AM, Al-Qaisieh B, Gould K, Bownes P, Smith J, Carey B, Bottomley D, Ash D.
    Int J Radiat Oncol Biol Phys; 2010 Jan 01; 76(1):50-6. PubMed ID: 20005453
    [Abstract] [Full Text] [Related]

  • 18. Interstitial irradiation for localized prostate cancer.
    Herr HW.
    Semin Urol; 1983 Aug 01; 1(3):222-8. PubMed ID: 6379805
    [No Abstract] [Full Text] [Related]

  • 19. [Interstitial therapy with 125 iodine seeds of prostatic cancer in elderly men].
    Huttner S, Gleichmann R, Scholz R, Antes G.
    Bildgebung; 1991 Aug 01; 58 Suppl 1():65-6. PubMed ID: 1799853
    [Abstract] [Full Text] [Related]

  • 20. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features.
    Dattoli M, Wallner K, True L, Cash J, Sorace R.
    Cancer; 2007 Aug 01; 110(3):551-5. PubMed ID: 17577217
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.